BioNTech (NASDAQ:BNTX) Given New $145.00 Price Target at HC Wainwright

BioNTech (NASDAQ:BNTX - Free Report) had its price objective reduced by HC Wainwright from $150.00 to $145.00 in a report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for BioNTech's Q1 2025 earnings at ($2.34) EPS, Q2 2025 earnings at ($2.52) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at $0.58 EPS and FY2025 earnings at ($5.51) EPS.

Other equities research analysts have also issued reports about the company. Wells Fargo & Company began coverage on BioNTech in a research note on Wednesday, December 11th. They set an "overweight" rating and a $170.00 price target for the company. Citigroup assumed coverage on shares of BioNTech in a research note on Thursday, March 13th. They issued a "buy" rating and a $145.00 target price on the stock. Truist Financial assumed coverage on BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 price target for the company. Morgan Stanley dropped their price target on BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 11th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, BioNTech presently has an average rating of "Moderate Buy" and a consensus price target of $143.44.

Remove Ads

BioNTech Trading Down 4.3 %

NASDAQ BNTX traded down $3.96 during trading hours on Tuesday, hitting $88.05. 1,035,719 shares of the company were exchanged, compared to its average volume of 841,431. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average price of $108.81 and a 200 day moving average price of $112.88. The stock has a market cap of $21.13 billion, a PE ratio of -41.93 and a beta of 1.07.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same period in the previous year, the firm earned $1.90 earnings per share. BioNTech's quarterly revenue was down 19.5% compared to the same quarter last year. Analysts forecast that BioNTech will post -3.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of BioNTech by 22.2% in the fourth quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after purchasing an additional 1,401,547 shares during the period. Flossbach Von Storch SE increased its holdings in BioNTech by 1.1% in the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock worth $502,160,000 after buying an additional 47,236 shares during the period. Capital International Investors raised its position in BioNTech by 38.6% during the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock worth $161,304,000 after buying an additional 394,434 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in BioNTech during the 4th quarter valued at approximately $69,999,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in BioNTech by 632.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock valued at $57,191,000 after acquiring an additional 433,388 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.